About Zinc finger C3HC-type protein 1
Zinc finger C3HC-type protein 1 (ZC3HC1) is a protein
from Homo sapiens identified by UniProt accession
Q86WB0, 502 residues long.
MolForge cross-references it against 0 known binders and
191 disease associations.
Target properties
| Protein name | Zinc finger C3HC-type protein 1 |
| UniProt accession | Q86WB0 |
| Gene | ZC3HC1 |
| Organism | Homo sapiens |
| Length | 502 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (191)
Diseases linked to this target (Open Targets).
- cancer · score 0.46
- neurodegenerative disease · score 0.45
- coronary artery disease · score 0.40
- hemoglobin measurement · score 0.38
- platelet count · score 0.38
- diastolic blood pressure · score 0.37
- eosinophil count · score 0.37
- sex hormone-binding globulin measurement · score 0.37
- hematocrit · score 0.36
- neutrophil count · score 0.36
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q86WB0-F1 | alphafold | PREDICTED | 68.28 | — |
Amino-acid sequence (502 residues)
MAAPCEGQAF AVGVEKNWGA VVRSPEGTPQ KIRQLIDEGI APEEGGVDAK DTSATSQSVN GSPQAEQPSL ESTSKEAFFS RVETFSSLKW AGKPFELSPL VCAKYGWVTV ECDMLKCSSC QAFLCASLQP AFDFDRYKQR CAELKKALCT AHEKFCFWPD SPSPDRFGML PLDEPAILVS EFLDRFQSLC HLDLQLPSLR PEDLKTMCLT EDKISLLLHL LEDELDHRTD ERKTTIKLGS DIQVHVTACI LSVCGWACSS SLESMQLSLI TCSQCMRKVG LWGFQQIESS MTDLDASFGL TSSPIPGLEG RPERLPLVPE SPRRMMTRSQ DATFSPGSEQ AEKSPGPIVS RTRSWDSSSP VDRPEPEAAS PTTRTRPVTR SMGTGDTPGL EVPSSPLRKA KRARLCSSSS SDTSSRSFFD PTSQHRDWCP WVNITLGKES RENGGTEPDA SAPAEPGWKA VLTILLAHKQ SSQPAETDSM SLSEKSRKVF RIFRQWESLC SC
Explore Zinc finger C3HC-type protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets